Addressing Accessibility and Affordability of CELL & GENE THERAPIES 
Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry. Quite a few companies in the field are making remarkable advancements toward potentially curative treatments for challenging diseases using groundbreaking science. With lower R&D development costs than in advanced markets, China is becoming an attractive market for the development of CGT, and therefore may emerge as a strong competitor of overseas-made CGT, notes a 
GlobalData report. Bayer AG, recently announced the global expansion of its life science incubator network, Bayer Co. Lab, to Shanghai, China and Kobe, Japan. The new site in China will focus on oncology and CGT innovations. While India lags behind China in the production of cell and gene therapies, a wave of new biotech startups is emerging to address this challenge. Immuneel Therapeutics and ImmunoACT are currently developing CAR-T cell therapies. The latter’s  NexCAR19 therapy received approval from India's Central Drug Standards Control organisation (CDSCO) for treating relapsed or refractory B-cell lymphomas and leukaemia. Despite a steady stream of regulatory approvals and promising  growth prospects, the high manufacturing costs associated with these therapies often render them inaccessible to the majority of patients. To address this issue, companies are actively striving to streamline and optimise the highly intricate and labour-intensive process of cell and gene therapy manufacturing.

ENGENDERING INCLUSIVITY & DIVERSITY IN LIFE SCIENCES
We are celebrating International Women's Day this time around by spotlighting women's roles and challenges in life sciences, spanning leadership, clinical trials participation and pay parity issues. Section I of the story highlights remarkable women leading public sector organisations in life sciences in APAC. Section II discusses the persistent issue of pay parity in the sector, while the final section tackles issues related to women in clinical trials. Let's delve deeper.

Next-Gen ADCs as Precision Weapon Against Cancer
Antibody-Drug Conjugates (ADCs) are emerging as a crucial frontier in targeted cancer care. Although the first ADC was approved in 2000, the space has experienced a renaissance in recent times. Major pharmaceutical players like Novartis and Pfizer, including startups, are announcing deals in this space almost every day. Within the Asia-Pacific (APAC) region, China stands at the forefront of ADC drug development. GlobalData reports that numerous domestic companies in China are actively shifting their focus towards the creation of pioneering ADC-based treatment options, particularly for solid tumours like breast, gastric, and bladder
cancer. When we observe World Cancer Day on February 4, we explore the promising world of next-gen ADCs, exploring advancements and unravelling the advantages they offer compared to other therapies like cell and gene therapies.

Transformative Life Sciences Trends for 2024
The intersection of tech and healthcare holds immense potential for the life sciences industry. From generative artificial intelligence (GenAI), augmented reality (AR), and virtual reality (VR) to decentralised clinical trials and 3D printing, we delve into the latest tech trends such Cellular Multi-Omics, Gene Editing CRISPR Technologies, Decentralised Clinical Trial (DCTs), digital health, digital twins, smart manufacturing, and wearables poised to lead the life sciences landscape in 2024.

Buoyant Life Sciences Sector Emerges Stronger
As we bid farewell to another eventful year in the world of life sciences, it’s time to look back at the whirlwind of advancements and changes that have shaped the industry in 2023. Back in January this year, we interacted with leaders from various market segments who shared their insights into what the year held for their particular spheres. Let’s recap the 2023 predictions and find out if they panned out as predicted.

Addressing Diabetes-related  complications 
Southeast Asia is currently home to 90 million adults diagnosed with diabetes, and this number is expected to reach 113 million by 2030, according to the International Diabetes Federation (IDF) Diabetes Atlas 2022. Out of these 90 million, 46 million remain undiagnosed. The delayed diagnosis of diabetes leads to prolonged periods of uncontrolled  hyperglycemia, resulting in severe diabetes related complications, such as diabetic retinopathy (eye problems), diabetic foot ulcers (DFU), diabetic nephropathy (kidney problems), and cardiovascular diseases. The vast number of people affected by diabetes, including many who are undiagnosed or at risk, presents a massive market for innovative treatments and preventive solutions. New technologies and novel treatment approaches offer hope for better prevention and management of these diabetes-related complications.

Big Pharma Sets Sights on Middle East
The Middle East, traditionally renowned for its prominence in the travel and oil and gas industries, is shifting its focus towards the life sciences sector. The region is actively forging numerous partnerships, initiatives, and programmes, and spending billions to establish itself as a major hub for life sciences. As the population of the region continues to grow and age, there is a clear and growing demand for locally manufactured medical treatments and products. Big pharma players are also making substantial inroads into the Middle East, with the Kingdom of Saudi Arabia (KSA), 
Qatar, and the United Arab Emirates (UAE) leading the way in these regional efforts. Areas such as rare diseases, genomics, personalised medicines, and pharmaceutical manufacturing have emerged as hotspots in the Middle East. Let’s delve deeper 
into the region’s endeavours to become a biotech powerhouse.

Multipronged Approach Against Alzheimer’s Disease
In July 2023, Eisai and Biogen received full traditional approval from the United States Food and Drug Administration (US FDA) for their Alzheimer’s drug Leqembi (lecanemab-irmb). This drug is the first to target the disease’s progression rather than merely addressing its symptoms. The approval has infused excitement and hope into the field of Alzheimer’s drug development, known for frequent drug failures. Alzheimer’s Disease (AD) is an escalating global health crisis. In 2020, the World Health Organisation (WHO) noted over 50 million people had dementia worldwide; 60 per cent of them lived in low- to middle-income countries. The Asia Pacific region bears a hefty burden with dementia care costs at $185 billion, straining healthcare in populous economies, according to ADI (Alzheimer’s Disease International). As we mark World Alzheimer’s Day this year on September 21, let’s take a stock of the advancements in the research and development in the Asia Pacific.

TAIWAN BIOMED INDUSTRY EYES $32B 
Biomedicine is a top priority for Taiwan, with the government aiming to position the country as the leading hub for biomedical research and development in the Asia-Pacific region. By 2025, Taiwan aims to create 20 new medicines, introduce 80 high-value medical devices to the market, and elevate the biomedicine industry into a trillion-NT-dollar (approximately $32 billion) sector. The government has taken various initiatives, established biomedicines clusters and tweaked policies to achieve this goal. Has the effort paid off? How far has the country come to achieve its goals?

TECH-POWERED WAR ON AMR
The consistent increase in antimicrobial resistance (AMR) is threatening to undo many of the gains of modern medicine. The situation is particularly alarming in the Asia Pacific region, which could witness around 50 per cent of global annual AMR-related mortality by 2050. Around 62 per cent of antibiotics in the region are used without prescriptions, indicating inappropriate usage and significantly increasing
the risk of AMR strain emergence, according to a report from LEK Consulting Group. All this makes the region an epicentre of AMR and its consequences. In response to the growing threat, countries in the region have taken steps to tackle the AMR threat. These include a National Action Plan on AMR (NAP-AMR), antimicrobial stewardship efforts, diagnostics surveillance etc. However, the million-dollar
question is whether these steps will be effective and enough. Let’s find out.

TAPPING FULL POTENTIAL OF NANOPARTICLES
Nanoparticles are another powerful tool in the biotech industry’s arsenal for targeted drug delivery. Their extremely small size, measured in nanometres, makes them highly effective carriers for therapeutic agents. These miniature carriers can be customised to encase drugs, benefiting from their biocompatibility, controlled release capabilities, stability, and low toxicity. The precision offered by nanoparticles opens up a world of possibilities for treating various diseases, including infectious diseases, cancer, and neurological disorders. These tiny particles offer tremendous
potential for targeted drug delivery, enhanced therapeutic efficacy and precise disease targeting. Moreover, the global market for nanoparticle drug delivery is projected to grow significantly, reaching $123.6 billion by 2025, according to BCC Research. Let’s deep dive into the fascinating field of nanomedicines, advancements and challenges in nanoparticle drug delivery.

$15B Pharma R&D Spends ROCKS APAC
Earlier seen as a generic powerhouse, Asia is now an important hub for pharma R&D innovation. The total gross expenditure by major companies on R&D across the Asia Pacific region crossed the $15 billion mark (approx) in 2022. Oncology, neurology, and immunology continue to draw a significant chunk of this investment. BioSpectrum Asia examines how top pharma companies in the region are
allocating their R&D budgets and the impact of the ensuing R&D endeavours on the industry.

A World Sans MALARIA
Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people. According to a latest report on malaria from the World Health Organisation (WHO), there were approximately 5.4 million cases and 9000 deaths in the region in 2021. The SEA region has nine countries where malaria is prevalent, and their contribution to the global burden of malaria cases is two per cent. India is the main contributor to the malaria cases in the region, accounting for 82.5 per cent of them, followed by Indonesia with 15.6 per cent, and Myanmar with 1.6 per cent. These three countries were responsible for almost all of the malaria cases in the region, making up 99.7 per cent of the total estimated cases. Governments, healthcare organisations, and communities are implementing innovative strategies, technologies, and programmes that can help curb the spread of malaria. Though these efforts were hampered because of COVID-19, in 2022, the WHO South-East Asia Region renewed its commitment to eliminate malaria by 2030, with countries pledging accelerated action and greater efforts at the sub-national and community levels. Other parts of Asia also progressed well. China was declared Malaria free in June 2021, after 70 years of fighting. In its fights against malaria, Asian countries have recently
announced significant investment including a $1.9 million investment in February 2023 by Japan’s GHIT Fund for the research and development of a new malaria drug, and a $1 million contribution by Singapore’s Ministry of Health to the Global Fund to fight AIDS, TB, and Malaria, announced in December 2022. While observing World Malaria day on April 25, let’s explore the current status of Asia’s malaria elimination efforts, highlighting the progress made and strategies needed for a malaria-free future.

HOW PLAUSIBLE IS ENDINGHOW PLAUSIBLE IS ENDING TB SCOURGE?
Tuberculosis (TB) has been the leading cause of death from a single infectious agent, ranking above HIV/AIDS for a long time. And, presently, Asia Pacific is right in the thick of it. South-eastern Asia (SEA) is home to 26 per cent of the world’s population with a 43 per cent burden of TB incidence, according to the World Health Organisation’s (WHO) global TB report 2021. Over the last three years, countries around the world, including in Asia and the Pacific, have faced double pandemics –COVID-19 and TB. Unfortunately, during this time, progress toward TB elimination stalled and, in some cases, reversed. COVID-19 made it harder for people to access TB diagnostics and care, eading to increases in cases and deaths since 2019. Four countries, India, Indonesia, the Philippines, and Myanmar accounted for most of the estimated increase in TB deaths, globally, in 2021. Not all is lost though. The countries in the region, especially India and Indonesia, have renewed their efforts to eliminate TB. India launched the TB Free India campaign – a plan to eliminate tuberculosis by 2025, five years ahead of the target set by the UN’s sustainable development goals. Indonesia received a $300 million loan from the World Bank to improve overage, quality and efficiency of TB response in the country. When observing World TB day this year on March 24, let’s take stock of the progress made by Asian countries in eliminating this dreaded disease and the way forward.

CANCER THERAPEUTICS GAINING GROUND IN APAC
Cancer, the leading cause of death in most parts of the world, is a veritable Achilles heel for the pharma industry. Not surprising that pharma companies continue to dedicate a significant part of their R&D budget for Oncology. Cancer medicine spending rose to $185 billion globally in 2021 and is expected to reach more than $300 billion by 2026, as per IQVIA. China’s oncology spending now exceeds the rest of emerging countries and is driven by expanded access to new therapies
and offset by lower prices. Chinese and other Asian cancer drug developers are at the forefront of driving innovation in this space. The focus of cancer treatment is rapidly shifting from a traditional one-size-fits-all approach to precision medicine, tailored treatments for individual patients. The next wave of innovations making headlines in the cancer space include immunotherapies, vaccines, CAR-T therapies, PD-1/L1 inhibitors, light-activated drugs etc. Many drug makers in Asia are investing in new science and hope to develop the next holy grail in oncology. Let’s take a deep
dive into the status of cancer drug research and development in the Asia Pacific (APAC).

Life Sciences Trends to Watch for in 2023
The past two years have been a rollercoaster ride for the global economy and the pharma industry hasn’t been impervious to the major financial upheavals either. Yes, it’s the Pandemic and Post-Pandemic world that’s been influencing people from all walks of life and industries, alike. Buzzwords notwithstanding, we do have to thank the pandemic situation that forced all stakeholders to innovate and pool the best and brightest resources to keep the Life Sciences industry thriving. While all other industries either lost steam in their growth plans, pharma boomed, not unlike the Phoenix rising from the ashes. It is this streak of resilience and growth that we want industry insiders to comment on. With curtains down for 2022, it’s time to look to the new year without the trepidation of the looming ‘Great Reset’. On an upbeat note, BioSpectrum brings you 23 trends and projections for 2023 that could reshape and influence our collective future.

BioSpectrum Asia Excellence Awards 2022 
Asia has, indeed, become the new hub for potential growth and innovation, with no signs of losing steam. To appreciate the Asian companies and individuals for their commendable performance and achievements during Calendar Year (CY) 2021, BioSpectrum Asia Excellence Awards 2022 ceremony was held at Lavender Ball Room, Hotel Fort Canning in Singapore on December 2, 2022. These awards are an extension to observe and highlight the winners in the long battle to tackle the world’s emerging health problems and find solutions. Since 2020 and 2021 were majorly affected by COVID-19, we saw the industry players relentlessly working towards developing novel solutions in the form of diagnostic tests, vaccines, monoclonal antibodies, drugs etc. to fight the emergency.

Invincible Diabetes Turns APAC Into Pharma Goldmine
There are over 235 million diabetic patients in Asia. China and India account for almost half of the world’s diabetic population. By 2030, without intervention, both China and India combined will have nearly half a billion diabetics. These are grim figures but for pharma firms, they represent a huge opportunity, and big pharma firms are spending billions in search of the next blockbuster drug for diabetes,
according to the estimates from Singapore-based Asian Diabetes Prevention Initiative (ADPI). The diabetes care drugs market is highly fragmented in Asia Pacific (APAC) region with a few major manufacturers gaining presence in major countries of the APAC market, while the remaining market comprises other local or regionspecific manufacturers. Mergers and acquisitions that happened between players in the recent past helped companies strengthen their market presence, as well as drive innovations, helping the diabetes drugs market to increase in the APAC region. Let’s look at who owns the more significant piece of the pie and the competitive landscape of diabetes treatment in the region.

Can Technology Efface SLEEP DISORDERS?
The world is wide awake. Sleep disorders are on the rise globally and the Asia Pacific is no
different. There are numerous studies documenting how sleep loss is rampant and becoming an epidemic. Approximately 45 per cent of people worldwide don’t get enough sleep. Asians have the shortest average sleep time, according to researchers from Flinders University, Australia. To combat these, firms are now turning to technology. The emergence of wearables, smart devices, trackers, and patches has made widespread remote sleep monitoring possible. Insights gained from the data collected by these devices are used to improve understanding of sleep and create preventative sleep loss strategies. Let’s look at how healthcare firms are trying to unlock the science of sleep disorders diagnosis and treatment by leveraging new tech.

INCUBATORS IGNITING BIOSCIENCE ECOSYSTEM
Incubators and accelerators are driving small and medium enterprises (SMEs) in Asia
through the development of novel therapeutics and encouraging innovations and
commercialisation. Biotechnology incubators provide a stimulating environment that
attracts investors, talent, and companies to collaborate on research, thereby fostering
industry growth. While the appetite for laboratory space is constantly growing among
biotech ventures, countries in the Asia Pacific (APAC) region are actively investing
to construct life science hubs that foster innovation strategies and strengthen R&D
capabilities. Let’s explore prominent startup incubators and accelerators in key APAC
economies that are cultivating biotech innovations to create unicorns.

Keeping Pace with MUTATING VIRUSES 
A surge in the pandemic has forced the pharma industry to deliver a wide-spectrum vaccine to fight mutation-prone SARS-CoV-2, pledging to prevent future outbreaks. WHO states that the most extensive vaccination campaign in history is providing prophylactic results by delivering more than 12 billion doses of the COVID-19 vaccine, protecting 60 per cent of the global population as of June 2022. Now the next-generation COVID-19 vaccines are countering the
challenge of enhancing the immune response to tackle the emerging COVID-19 variants. It is therefore imperative to remain vigilant and upgrade vaccine candidates to emerging virus sublineages. In order to gain a competitive position in the market, vaccine manufacturers are investing in advanced platform technologies. Let’s take a closer look at some of these leading vaccines approved in APAC as broad spectrum virucide inhibitors.

HOW IS BIOMANUFACTURING DRIVING CDMO MARKET?
A successful business model for the pharmaceutical industry is driven by the outsourcing trend, making contract evelopment and manufacturing organisations (CDMOs) an integral component of drug development value chains. Increasing regulatory complexity, high development costs, and fierce competition have driven drug companies to leverage CDMOs to accelerate their go-to-market strategy, and Asia Pacific (APAC) is not an exception. Let’s navigate through prime achievements and potential trends in the APAC CDMO arena which helped the world heal during the pandemic and is further helping to build a resilient health system

Targeting Optimal DRUG DELIVERY
In recent years, several innovations have emerged around long-acting formulations and medical device development to improve patient compliance. Consequently, the growing need for controlled drug release coupled with technological advancements in pharmacology is promoting the adoption of novel drug delivery systems (NDDS). It is now crucial for Asia Pacific (APAC) drug formulators to learn and act upon these advances in therapeutic modalities that address long-standing bioavailability, dosage, and ingestion challenges of drug components to remain competitive in the global market. Simultaneously, it’s essential to optimise the therapeutic efficacy and safety profiles of a drug by regulating dosage parameters, while DDS plays an important role in administering drugs, vaccines, and therapeutic agents. Optimising these techniques enhance the performance
efficacy ratio of medications by economically managing therapeutics assets. Let’s examine recent advancements in drug delivery modalities that are greatly encouraging stakeholders’ collaboration among innovators, manufacturers, investors, and contract development and manufacturing companies  CDMOs) who are capitalising on competitive advantages.

Oz BUDGET BOLSTERS HEALTHCARE
Circumstances have continued to evolve as the COVID-19 Omicron variant has added further pressure to Australia’s healthcare sector, as well as increasing supply chain disruptions, bringing about staff shortages and reducing household spending. With a Federal election due on May 21, 2022 to elect members of the 47th Parliament of Australia, Josh Frydenberg , Treasurer of the Commonwealth of Australia presented the Federal Budget on March 29. The Coalition government
led by Scott Morrison is investing in a stronger health system as part of its plan for a stronger future through a record $132 billion in 2022–23 Budget, increasing to $140 billion in 2025–26, with a total commitment of $537 billion over the next four years. This record funding will ensure Australians have access to improved healthcare, when and where they need it, helping them to lead healthier lives, with improved health outcomes and to provide ongoing protection against COVID-19.

WHY HOLOMEDICINE IS RAPIDLY GAINING GROUND
Medical holography has emerged as one of the most promising applications in the medical industry. Holographic imaging technology is advancing healthcare, life sciences, biomedical research as well as medical training and education. Mixed Reality (MR) applications are gradually making a progressive impact on healthcare deliveries with precise quantitative measurement of human internal anatomy elements in 3D holograms geometries displayed in actual physical space. Holographic 3D technology renders medical professionals with advanced diagnostic capabilities and surgical planning, by allowing them to slice virtual tissue, organs, and other body parts at various angles. Holomedicne advances access to percutaneous procedures without invasive needle techniques. Surgeons across the world are now curious to explore medical holograms to enhance the efficiency of complex surgeries.

BREAKING DOWN DISPARITIES
Women continue to sustain the quest to make a mark in the workplace and balance their personal life. Pandemic or not, woman power has not diminished one bit, and it shows in their exemplary achievements in India and the rest of the world. On the occasion of Women’s Day, BioSpectrum Asia salutes 20 inspiring leaders of the life sciences industry in the APAC region, for motivating others around them, breaking the glass ceiling and paving their own paths in 2021. These 20 women are in their respective fields, inspiring not just their employees and the people around them, but other women and the next generation of women leaders

BOOM OR BUST FOR ASIAN HEALTHCARE
Asia Pacific (APAC) is leaping with novel innovations while connecting the APAC market with global trends. Life sciences sector remains an attractive industry for investment from both strategic players and financial investors. The accelerated R&D activities amidst the pandemic attracted both outward direct investment (ODI) and foreign direct investment (FDI) in potential bio-pharma sectors at an estimated size of $40.25 billion in 2021. The surge in the pandemic is burgeoning consumer demand for innovative and potential healthcare products with the emerging digital health tech market. Thus, it’s essential to statistically analyse the perspective of the investment attractiveness in the APAC economy and translate it into a quantitative score to benchmark the performance of innovation and investments. Let’s gather some industry perspective on policy strengths and challenges in the markets for different stakeholders.

DIGITAL RESET
Nothing could have prepared the world for the unprecedented chain of events over the past two years. We prefaced 2020 and 2021 saying anything is possible, but no one saw this level of hyper volatility completely disrupting business and life as we know it. While the world is now firmly planted in a digital-format, the economic and business outlook for 2022 will remain highly fluid owing to the pandemic. Moreover, it is indeed very likely that in 2022, the majority of Asia Pacific’s GDP will be coming from digital products, services, and experiences across industries, with life scien

Focusing on VIGILANCE & PREPAREDNESS
Despite advances in development of countermeasures such as diagnostics, therapeutics and vaccines, world travel and increased global interdependence have added layers of complexity to containing infectious diseases. COVID-19, an outcome of weaponisation by genetic manipulation as part of ‘gain of function’ research, had brought the entire world to its knees in less than six months. Now, researchers and policymakers are being more vigilant towards surveillance and management of emerging infectious disease threats, and revisit global mechanisms for the control of pandemic disease. In addition to other countries across the globe, 2021 saw many initiatives taken by the APAC region to strengthen their capacities for effective preparedness and for the prevention of new and existing infectious diseases.

Malaysia spearheads BIOECONOMY Initiatives
Malaysia is strategically positioned to make the country a much-sought-after hub of Bioeconomy. In 2020, it completed the final phase of the National Biotechnology policy (NBP), and is betting on its bioeconomy sector to drive a robust economic recovery through programmes and initiatives of Bioeconomy Corporation. As a regional leader in this sector, being the second country in Asia and the first country in South East Asia to announce a national bioeconomy initiative, Malaysia has already set the ball rolling. Moreover, in line with the National Recovery Plan, it has also framed a Bioeconomy blueprint to address pandemic challenges and to boost various sectors that are crucial to the economy. The country is poised to globalise bioentrepreneurship by bestowing fiscal incentives and grants through special BioNexus Status, effectively making it a major global player to reckon with, in the bioeconomy space.

BioSpectrum Asia April 2024

March 2024

BioSpectrum Asia Feb 2024

BioSpectrum Asia January 2024

December 2023

November 2023

October  2023

September 2023

August 2023

July 2023

June 2023

May 2023

April 2023

March 2023

February 2023

January 2023

December 2022

November 2022

October 2022

September 2022

August 2022

July 2022

June 2022

May 2022

April 2022

March 2022

February 2022

January 2022

December 2021

November 2021

BioSpectrum Asia Magazine is a monthly magazine published by MM Activ Sci-Tech Communication in India. It is a leading biotechnology magazine in Asia, covering a wide range of topics related to the biotechnology industry, including:

* Biotechnology news and trends: BioSpectrum Asia covers the latest biotechnology news and trends from India and around the world.
* Biotechnology company profiles and interviews: The magazine profiles leading biotechnology companies in Asia and interviews their CEOs and other top executives.
* Biotechnology research and development: BioSpectrum Asia covers the latest biotechnology research and development from academic institutions and pharmaceutical companies.
* Biotechnology product reviews: The magazine reviews the latest biotechnology products and services.
* Biotechnology industry events: BioSpectrum Asia covers biotechnology industry events from around the world.

BioSpectrum Asia Magazine is a must-read for anyone who wants to stay informed about the latest advances in biotechnology and their potential to impact the world around us.

1. You agree that the use of Magzter.com, the application and its services, are at solely at your own risk. Neither Magzter.com nor its associates nor employees nor third party content providers guarantee that the service will be completely uninterrupted or error-free or foolproof against miscreant activities. Nor do they warranty that you will get the exact results as expected or promised by the website or product.

11. THE SERVICE AND ALL PUBLICATIONS ARE PROVIDED ON AN 'AS IS' AND 'AS AVAILABLE' BASIS. MAGZTER, ITS AFFILIATES, SUPPLIERS, LICENSORS AND AGENTS EXPRESSLY DISCLAIM ALL WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. WITHOUT LIMITING THE FOREGOING, NEITHER MAGZTER NOR ITS AFFILIATES, SUPPLIERS, LICENSORS OR AGENTS, MAKES ANY WARRANTY THAT (I) THE SERVICE WILL MEET YOUR REQUIREMENTS, (II) THE SERVICE WILL BE UNINTERRUPTED, TIMELY, SECURE, OR ERROR-FREE, (III) THE INFORMATION THAT MAY BE OBTAINED FROM THE USE OF THE SERVICE OR THAT MAY BE CONTAINED IN THE PUBLICATIONS WILL BE ACCURATE OR RELIABLE, OR (IV) THE QUALITY OF ANY PUBLICATIONS OR THE SERVICE WILL MEET YOUR EXPECTATIONS. YOU ARE SOLELY RESPONSIBLE FOR OBTAINING AND MAINTAINING RELIABLE INTERNET CONNECTIVITY AND YOUR DEVICE. MAGZTER IS NOT RESPONSIBLE FOR YOUR INABILITY TO DOWNLOAD CONTENT. ANY MATERIAL DOWNLOADED OR OTHERWISE OBTAINED THROUGH THE USE OF THE SERVICE IS DONE AT YOUR OWN DISCRETION AND RISK AND YOU WILL BE SOLELY RESPONSIBLE FOR ANY DAMAGE TO YOUR COMPUTER SYSTEM OR MOBILE DEVICE OR LOSS OF DATA THAT RESULTS FROM THE DOWNLOAD OF ANY SUCH MATERIAL. NO ADVICE OR INFORMATION, WHETHER ORAL OR WRITTEN, OBTAINED BY YOU FROM MAGZTER OR THROUGH OR FROM THE SERVICE SHALL CREATE ANY WARRANTY.

2. You will maintain and promptly update that information to keep it true, accurate, current and complete. You are responsible for maintaining the confidentiality of your account and password and for restricting access to your computer, and you agree to accept responsibility for all activities that occur under your account, including the selection and use of all content and services.

2.You will maintain and promptly update that information to keep it true, accurate, current and complete. You are responsible for maintaining the confidentiality of your account and password and for restricting access to your computer, and you agree to accept responsibility for all activities that occur under your account, including the selection and use of all content and services.

3. In no event will Magzter.com or any person or entity or third party involved in the creation, production and distribution of the content on the website and the application be liable in contract or legally for any damages, including and not limited to, direct, indirect, incidental, special, and consequential incurred to you while or on using Magzter.com. By registering on the website or downloading the application, you agree that the provisions mentioned in this section shall apply to all use of and content on the website and the application.

3. Without prior written or authorised permission from Magzter, you should not modify, copy, distribute or sell any content obtained from Magzter as everything published here is the proprietary property of Magzter or its licensors. As such unauthorised use may also violate applicable laws including copyright and trademark laws, Magzter strictly prohibits these and will terminate your access and account if any such illegal activity is proved or detected. You should also stand liable for the damages caused by these unauthorised activities. Except as permitted by the Publication's lawful owner, you acknowledge that you do not acquire any ownership rights by downloading Publications accessed through the Service. Except as explicitly required under copyright law or permitted by the features of the Service you may not modify, reverse engineer, publish, transmit, display, participate in the transfer or sale, create derivative works of, or in any way commercially exploit or provide to a third party the content of the App, the Publications, or any portion of them without the express permission of Magzter and the owner of such content. We do not grant you any licenses, express or implied, to the intellectual property of Magzter or Magzter's licensors.

5. You specifically acknowledge that Magzter.com is not liable for any kind of defamatory or offensive or illegal conduct of other users or third parties or their content and that the risk of injury from the foregoing rests entirely with you.

8. Magzter reserves all rights to monitor the content published and inputted by you for the purpose of determining whether you are compliant with these terms and conditions and other operating rules determined by Magzter. Magzter has the right to take decisions about the content and delete them at its own will.

9. Magzter is a distributor and NOT a publisher of the Publications and so Magzter has no editorial control over the content, including opinions, advice, statements, services, offers etc., that is represented in the magazines. So Magzter will not take responsibility for the accuracy or the reliability for any information or facts provided therein or that is made available through the service, by anyone other than authorised Magzter employees who are acting on their official capacities. Accordingly, we have no editorial control over the Publications. Any opinions, advice, statements, services, offers or other information or content expressed or made available by third parties, including those made in Publications offered by the Service, are those of the respective author(s) or publisher(s) and not of Magzter. Magzter will not be liable for any loss or damage caused by your reliance on information obtained through the Service or from the Publications. The Service may contain links to other Internet sites and third-party resources and Magzter does not assume any responsibility or liability for communications or materials available at such linked sites. These links are provided for your convenience only. You are solely responsible for understanding any terms and conditions that may apply when you visit or place an order through a third-party site.

Details of the objectionable content, including its link on our platform

Download your favorite titles and read them offline, anytime and anywhere

Gift your loved ones with a Magzter Gift Card instantly and give them the freedom to read their favorite magazines and newspapers from thousands of best-selling titles.

Gift your loved ones with a Magzter Gift Card instantly and give them the freedom to read their favorite magazines from thousands of best-selling titles.

Gift your loved ones with a Magzter Gift Card instantly and give them the freedom to read their favorite magazines from {{magCount}} best-selling international titles.

Girish Ramdas is the Co-founder and CEO of Magzter, a New York based startup that has been making waves in the global digital publishing business. Magzter has crossed 80 million users since its inception in 2011 from more than 150+ countries with 1000s of magazines, newspapers and books from more than 4,500 publishers worldwide. He has more than 25 years of experience in cross-platform publishing, including print, mobile, and Web development. During this period, he has co-founded and run three successful start-up businesses. He has enabled magazine companies to go digital and helps them monetize their content across the digital world. Girish's deep industry experience in online, mobile and publishing ecosystems has made him an expert in acquisition, marketing and monetizing digital content across platforms globally.

In the event that you encounter any objectionable content on our platform, we have put in place a grievance redressal policy to address your concerns.

Magzter Inc. (“Company”, “we”, “us” or “our”) knows that you care about how your personal information is used and shared. Please read the following privacy policy (the “Policy”) to learn more about our privacy practices. By visiting any of the websites operated by the Company, and any sub-domains thereof, or using any of our mobile applications and other methods of content distribution (collectively, the “Service”), you acknowledge that you accept the practices and policies outlined in this Policy, and you hereby consent that we will collect, use, and share your information in the following ways.

Magzter Inc. is the World's largest and fastest growing self-service, cross-platform digital newsstand with over 80 million users since its inception in 2011 and thousands of magazines and newspapers across 40+ categories and 60+ languages. Headquartered in New York, Magzter has its local presence in Amsterdam, London, Mexico City, Chennai, Mumbai, New Delhi, Bengaluru, Singapore, and will soon be expanding to other countries. Founded by global entrepreneurs, Girish Ramdas and Vijay Radhakrishnan in June 2011, Magzter enables magazine and newspaper publishers around the world to create and deliver digital editions of their titles to global consumers.

Magzter is committed to providing a safe and secure platform for our users. Please note that Magzter is merely a platform for publishers to distribute their content. We do not control or endorse the content published on our platform. We cannot be held responsible for the actions of our publishers or their content.

Magzter is not responsible for compensating any party that has suffered damages or incurred costs due to any content, or part of the content, that violates their rights. Magzter is not liable to face any legal action in civil court for any violation of rights caused by any content, or part of the content, that infringes the rights of a third party.

Magzter offers the world’s largest {{allyoucanread}} subscription service called {{gold}} which gives digital readers unlimited access to 8,500+ magazines and newspapers for a monthly subscription price. Magzter also has the largest number of stories in the world with its game-changing ezRead 2.0 feature for its apps, which enables smartphone and small-screen mobile users to enjoy magazine content the way it was meant to be enjoyed, with article text that is easy to read and is accompanied by stunning videos and high resolution photography.

Magzter offers the world’s largest “All-You-Can-Read” subscription service called Magzter GOLD which gives digital readers unlimited access to 8,500+ magazines and newspapers for a monthly subscription price. Magzter also has the largest number of stories in the world with its game-changing ezRead 2.0 feature for its apps, which enables smartphone and small-screen mobile users to enjoy magazine content the way it was meant to be enjoyed, with article text that is easy to read and is accompanied by stunning videos and high resolution photography.

Name

Note: This will only share the cover and the publication information, but not the content.

Please fill out this form if you need any help regarding publishing your content on Magzter

Prior to Magzter, he was the President of Dot Com Infoway (DCI) and Galatta Media. His duties included strategic marketing, partnership development, and monetizing content globally. DCI grew from a small team of 3 in 2000 to 300 by 2011 and was dealing with web, software and app development for clients globally.

Since we launched, Magzter has been committed to partnering with global organizations to provide the greatest possible newsstand technology & service to our customers. Whether you are looking to offer magazine subscriptions to your customer database or just want to learn more, Magzter is committed to helping your business grow. To find out more, please fill out the questionnaire below:

The DMCA allows us to restore the removed content if the party filing the original DMCA Notice does not file a court action against you within ten business days of receiving the copy of your Counter Notice.

This Policy covers Company’s treatment of personally identifiable information (“Personal Information”) and other information about you and your computer or device that Company gathers when you are accessing the Service. We may collect Personal Information from you, as explained in more detail below, and we use this Personal Information internally in connection with our Services, including to personalize, provide, and improve our products, services, content, and advertising, and to allow you to set up a user account and profile, to contact you, to fulfill your requests for certain products and services, and to analyze how you use the Services. In certain cases, we may also share some Personal Information with third parties, but only as described in point 4.

This title is included with your Magzter GOLD subscription

To analyze the quality of content and provide appropriate feedback to publishers

We have designated a Grievance Officer to address any complaints related to objectionable content.

We request that any complaint related to objectionable content be sent to the Grievance Officer through email to the above-mentioned email address. We also request that you provide the following details when making a complaint:

and the App that provides you the capability to order, subscribe to and receive the delivery of various magazines, books, news and magazine and publication related content (collectively known as 'Publications') and to have these digital versions of the Publications delivered to you

c. We also collect information associated with your use of the application in order to make personalized recommendations. If you provide your third-party account credentials to us, you understand some content and/or information in those accounts (“Third Party Account Information”) may be transmitted into your account with us if you authorize such transmissions, and that Third Party Account Information transmitted to the Service is covered by this Policy.

f. The Personal Information we collect allows us to respond to your requests, improve our products and services, customize the advertising and content you see, and communicate with you about new products.

is the World's largest and fastest growing self-service, cross-platform digital newsstand with over 87 million users since its inception in 2011 and thousands of magazines and newspapers across 40+ categories and 60+ languages. Headquartered in New York, Magzter has its local presence in Amsterdam, London, Mexico City, Chennai, Mumbai, New Delhi, Bengaluru, Singapore, and will soon be expanding to other countries. Founded by global entrepreneurs, Girish Ramdas and Vijay Radhakrishnan in June 2011, Magzter enables magazine and newspaper publishers around the world to create and deliver digital editions of their titles to global consumers.

n. We will also use usage information in order to ensure users adhere to our Terms of Use. For example, a user’s usage information will help us confirm that a user only downloads a magazine or other content a permitted number of times or to a permitted number of devices.

which gives digital readers unlimited access to 8,500+ magazines and newspapers for a monthly subscription price. Magzter also has the largest number of stories in the world with its game-changing ezRead 2.0 feature for its apps, which enables smartphone and small-screen mobile users to enjoy magazine content the way it was meant to be enjoyed, with article text that is easy to read and is accompanied by stunning videos and high resolution photography.

{{magzter}} is the World's largest and fastest growing self-service, cross-platform digital newsstand with over 87 million users since its inception in 2011 and thousands of magazines and newspapers across 40+ categories and 60+ languages. Headquartered in New York, Magzter has its local presence in Amsterdam, London, Mexico City, Chennai, Mumbai, New Delhi, Bengaluru, Singapore, and will soon be expanding to other countries. Founded by global entrepreneurs, Girish Ramdas and Vijay Radhakrishnan in June 2011, Magzter enables magazine and newspaper publishers around the world to create and deliver digital editions of their titles to global consumers.

BioSpectrum Asia- All Issues